Clinical trials using tocilizumab, a monoclonal antibody that neutralizes IL-6, show lower inflammation in individuals with acute coronary syndromes, compatible with a beneficial effect of overall IL-6 inhibition in patients with coronary artery disease [86,87,88]. Here, IL6 is linked to coronary artery disorder.